JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Home・Akcijų sąrašas・VolitionRX Ltd

VolitionRX Ltd

Uždarymo kaina

0.26 -7.14

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.25

Max

0.28

Pagrindiniai rodikliai
By Trading Economics
Pajamos	936K -5.4M
Pardavimai	221K 627K
Pelno marža	-857.414
Darbuotojai	75
EBITDA	1.3M -4.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+703.57% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-14M 33M
Ankstesnė atidarymo kaina	7.4
Ankstesnė uždarymo kaina	0.26

VolitionRX Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026-02-02 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-02-02 23:38; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026-02-02 23:28; UTC

Rinkos pokalbiai

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026-02-02 23:23; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026-02-02 22:57; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 22:22; UTC

Įsigijimai, susijungimai, perėmimai

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026-02-02 22:08; UTC

Rinkos pokalbiai

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026-02-02 21:51; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-02 21:49; UTC

Uždarbis

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026-02-02 21:39; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:36; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026-02-02 21:34; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:28; UTC

Įsigijimai, susijungimai, perėmimai

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026-02-02 21:23; UTC

Uždarbis

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026-02-02 21:19; UTC

Uždarbis

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026-02-02 21:17; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026-02-02 21:17; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:10; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:08; UTC

Uždarbis

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026-02-02 21:07; UTC

Uždarbis

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Net $608.7M >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Rev $1.41B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q EPS 24c >PLTR

2026-02-02 20:40; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Akcijų palyginimas

Kainos pokytis

VolitionRX Ltd Prognozė

Kainos tikslas

By TipRanks

703.57% į viršų

12 mėnesių prognozė

Vidutinis 2.25 USD 703.57%

Aukščiausias 3 USD

Žemiausias 1.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines VolitionRX Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių VolitionRX Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.